{"podcast":{"title":"Hematologic Oncology Update","slug":"hematologic-oncology-update-916423","podcast_index_feed_id":916423,"rss_url":"https://feeds.captivate.fm/hematologic-oncology/","website_url":"https://www.researchtopractice.com/browse-tumor-types/hematologic-oncology","image_url":"https://artwork.captivate.fm/385e0bc2-3e77-4650-a103-033cd89470e0/VM1-kJu7V4rmiKPVI6DGtcq3.png","author":"Dr. Neil Love","episode_count":161,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.","last_synced_at":"2026-09-26T04:24:25.521627+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423"},"episode":{"title":"Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus","slug":"chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus","published_at":"2026-09-12T13:00:00+00:00","page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus","show_page_url":"https://stenobird.com/podcast/hematologic-oncology-update-916423","url":"https://hematologic-oncology.captivate.fm/episode/6180-oncologytodaycml26","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/dcbd5f3c-def0-4db1-861d-51ecd2f6281f.mp3","summary":"Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKIs (10:23) Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23) Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14) Comparative efficacy of asciminib and other agents used to treat CML (40:01) Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53) Practical care strategies for CML patients; future developments (52:32) CME information and select publications","meta_description":"Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current the…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3589,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hematologic-oncology-update-916423/chronic-myeloid-leukemia-an-interview-with-prof-andreas-hochhaus.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}